Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bradley M Haverkos

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The Lancet. Haematology|February 28, 2020
Improved outcomes for extranodal natural killer T-cell lymphomaBradley M Haverkos, Pierluigi Porcu
International Journal of Radiation Oncology, Biology, Physics|November 18, 2021
SMILE and Beam OnSarah A Milgrom, Bradley M Haverkos
Cancers|March 11, 2023
Rational Targets of Therapy in Extranodal NK/T-Cell LymphomaAjay Major, Pierluigi Porcu, Bradley M Haverkos
Expert Opinion on Investigational Drugs|September 17, 2014
Investigational cancer drugs targeting cell metabolism in clinical developmentDouglas W Sborov, Bradley M Haverkos, Pamela J Harris
Frontiers in Oncology|July 3, 2019
Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL)Kelsey Sokol, Saritha Kartan, William T Johnson, et al.
Cancer Treatment and Research|January 1, 2019
Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS)Adetokunbo Oluwasanjo, Saritha Kartan, William Johnson, et al.
International Journal of Cancer|December 13, 2016
Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomasBradley M Haverkos, Ying Huang, Alejandro Gru, et al.
Frontiers in Oncology|July 3, 2015
The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous LymphomaKelly H Tyler, Bradley M Haverkos, Justin Hastings, et al.
Expert Review of Hematology|December 22, 2016
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?Pooja Virmani, Susan H Hwang, Justin G Hastings, et al.
FEBS Open Bio|May 9, 2023
CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL modelZhaohui Wang, Jihong Ma, Huiping Zhang, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The Lancet. Haematology|February 28, 2020
Improved outcomes for extranodal natural killer T-cell lymphomaBradley M Haverkos, Pierluigi Porcu
International Journal of Radiation Oncology, Biology, Physics|November 18, 2021
SMILE and Beam OnSarah A Milgrom, Bradley M Haverkos
Cancers|March 11, 2023
Rational Targets of Therapy in Extranodal NK/T-Cell LymphomaAjay Major, Pierluigi Porcu, Bradley M Haverkos
Expert Opinion on Investigational Drugs|September 17, 2014
Investigational cancer drugs targeting cell metabolism in clinical developmentDouglas W Sborov, Bradley M Haverkos, Pamela J Harris
Frontiers in Oncology|July 3, 2019
Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL)Kelsey Sokol, Saritha Kartan, William T Johnson, et al.
Cancer Treatment and Research|January 1, 2019
Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS)Adetokunbo Oluwasanjo, Saritha Kartan, William Johnson, et al.
International Journal of Cancer|December 13, 2016
Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomasBradley M Haverkos, Ying Huang, Alejandro Gru, et al.
Frontiers in Oncology|July 3, 2015
The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous LymphomaKelly H Tyler, Bradley M Haverkos, Justin Hastings, et al.
Expert Review of Hematology|December 22, 2016
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?Pooja Virmani, Susan H Hwang, Justin G Hastings, et al.
FEBS Open Bio|May 9, 2023
CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL modelZhaohui Wang, Jihong Ma, Huiping Zhang, et al.
Pageof 3